29 Jun 2020 Oblique Therapeutics and Targovax enter collaboration to target mutant RAS cancers by combining their ONCOS and Abiprot™ platforms Read more with our English Press Release: Oblique Therapeutics and Targovax enter collaboration to target mutant RAS
